Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Initial Assessment and Monitoring of Chronic Hepatitis C Patients

Essential Pre-Treatment Laboratory Panel

  • The American Association for the Study of Liver Diseases (AASLD) guidelines recommend obtaining a complete blood count, international normalized ratio, comprehensive hepatic function panel, calculated GFR, HCV genotype and subtype, and quantitative HCV viral load within 12 weeks prior to initiating antiviral therapy for patients with chronic hepatitis C and elevated transaminases 1
  • A complete blood count is essential for assessing baseline hematologic status and detecting thrombocytopenia, which may indicate advanced fibrosis, as recommended by the AASLD-IDSA guidelines 1, 2
  • The international normalized ratio (INR) is a critical marker of hepatic synthetic function, according to the AASLD-IDSA guidelines 1
  • A comprehensive hepatic function panel, including albumin, total and direct bilirubin, ALT, AST, and alkaline phosphatase, is necessary for assessing liver function, as recommended by the AASLD-IDSA guidelines 1
  • Calculated glomerular filtration rate (GFR) is required for medication dosing and monitoring renal function, as recommended by the AASLD-IDSA guidelines 1

Virologic Assessment

  • HCV genotype and subtype determination is necessary for selecting the appropriate treatment regimen, according to the AASLD-IDSA guidelines 1
  • Quantitative HCV viral load assessment is necessary for establishing baseline viremia, as recommended by the AASLD-IDSA guidelines 1

Additional Monitoring for Patients Not Achieving SVR

  • The AASLD-IDSA guidelines recommend monitoring hepatic function panel, complete blood count, and international normalized ratio every 6-12 months for patients who have not achieved sustained virologic response (SVR) 1, 2

Surveillance for Advanced Disease

  • Ultrasound surveillance for hepatocellular carcinoma (HCC) is recommended every 6 months for patients with advanced fibrosis (Metavir F3-F4), as recommended by the AASLD-IDSA guidelines 2
  • Endoscopic surveillance for esophageal varices is recommended if cirrhosis is confirmed, according to the AASLD-IDSA guidelines 2

Thyroid Function Monitoring

  • Thyroid-stimulating hormone (TSH) monitoring is only required if interferon-based therapy is planned, every 12 weeks during treatment, as recommended by the AASLD-IDSA guidelines 2, 5